MedTrace Logo

Plerixafor/G-CSF as Additional Agents for Conditioning Before HSCT in CGD Patients

NCT03547830 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2019-09-17

No results posted yet for this study

Summary

Treatment Study to assess of safety and efficiency of conditioning with Plerixafor and G-CSF as additional agents for prevention of graft failure after transplantation in patients with chronic granulomatous disease

Conditions

  • Chronic Granulomatous Disease

Interventions

DRUG

Plerixafor

Plerixafor for Conditioning before HSCT.

DRUG

Gcsf

GCSF for Conditioning before HSCT.

Sponsors & Collaborators

  • Federal Research Institute of Pediatric Hematology, Oncology and Immunology

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Month
Max Age
24 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-13
Primary Completion
2023-01-01
Completion
2023-01-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03547830 on ClinicalTrials.gov